Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Eckstein, Markus, Erben, Philipp, Kriegmair, Maximilian C., Worst, Thomas S., Weiß, Cleo-Aron, Wirtz, Ralph M., Wach, Sven, Stoehr, Robert, Sikic, Danijel, Geppert, Carol I., Weyerer, Veronika, Bertz, Simone, Breyer, Johannes, Otto, Wolfgang, Keck, Bastian, Burger, Maximilian, Taubert, Helge, Weichert, Wilko, Wullich, Bernd, Bolenz, Christian, Hartmann, Arndt and Erlmeier, Franziska (2019) Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer 106, pp. 234-243.Date of publication of this fulltext: 03 Sep 2021 10:10
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | European Journal of Cancer | ||||
| Publisher: | Elsevier | ||||
|---|---|---|---|---|---|
| Place of Publication: | OXFORD | ||||
| Volume: | 106 | ||||
| Page Range: | pp. 234-243 | ||||
| Date | 2019 | ||||
| Institutions | Medicine > Lehrstuhl für Urologie | ||||
| Identification Number |
| ||||
| Keywords | CISPLATIN-INELIGIBLE PATIENTS; PD-L1 IMMUNOHISTOCHEMISTRY; SINGLE-ARM; OPEN-LABEL; MULTICENTER; Bladder cancer; Urothelial carcinoma; PD-L1 assay; PD-L1; PD-1; Checkpoint inhibition | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 49227 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric